The Cannabis Health Symposium 2026 in Frankfurt offers a full‑day forum for clinicians, researchers, industry leaders and patient advocates. The meeting takes place on 4 November 2026 at Mainhaus and runs from 08:30 to 16:30. It focuses on Germany’s rapidly evolving medical cannabis landscape after the CanG reforms, which reshaped prescribing pathways, telemedicine access and patient demand.

The programme features twelve sessions and four panel debates, covering evidence, regulation, prescribing practice, pharmacy responsibilities, reimbursement challenges and public‑health insights. Speakers address the state of the German market, telemedicine debates, pharmaceutical quality standards, GMP and ASTM considerations, women’s health, chronic pain, mental health and European market comparisons.

The symposium attracts healthcare professionals, industry representatives and patient advocates, creating a multidisciplinary environment. Clinicians join to understand prescribing pathways, evidence and safeguards. Pharmacists attend to discuss product quality, substitution issues and evolving responsibilities. Industry leaders participate to explore competition, imports and regulatory trends. Researchers contribute public‑health data, including EKOCAN findings on cannabis reform.

Visitor numbers are not published, but the event targets Germany’s largest medical cannabis network and includes 12 months of MCCS membership, which signals strong professional engagement.

The symposium offers outstanding opportunities for networking and collaboration. Attendees gain direct access to decision‑makers shaping prescribing rules, telemedicine standards and pharmacy practice. Moreover, the event supports strategic dialogue between producers, distributors and regulators. As Germany’s market grows, participants can explore new business models, clinical pathways and quality frameworks. These discussions help align industry innovation with clinical needs and regulatory expectations.

Key industries represented include medical cannabis cultivation, pharmaceutical manufacturing, telemedicine providers, pharmacy networks, regulatory bodies and health‑data research. Their presence highlights the sector’s shift toward pharmaceutical rigor, digital access and evidence‑based policy. Together, these groups drive progress toward safer, standardized and accessible cannabinoid medicines in Germany.